The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
about
CIViC databaseNew frontiers in the treatment of colorectal cancer: Autophagy and the unfolded protein response as promising targetsActivation of RAS family members confers resistance to ROS1 targeting drugs.KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer.Optimized Multiplex Detection of 7 KRAS Mutations by Taqman Allele-Specific qPCR.Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancerCurrent practices and guidelines for clinical next-generation sequencing oncology testingA randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.Variation in KRAS driver substitution distributions between tumor types is determined by both mutation and natural selection.Impact of EGFR mutations and KRAS amino acid substitution on the response to radiotherapy for brain metastasis of non-small-cell lung cancer.Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation.KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.Text mining and network analysis of molecular interaction in non-small cell lung cancer by using natural language processingPredictive Tumor Biomarkers for EGFR Inhibitors
P2860
Q27612411-8B081194-A20A-4D57-8570-448C32E42063Q33731804-C39CCDA2-41FF-4ABF-B197-2DA4B2CC27E6Q34463388-450CC26F-868F-43C5-B306-7C3B420EB46AQ35098287-E5B8E9F6-9B9B-4713-B351-794CB08E8FE4Q36134534-3A7A72B2-249E-4DD6-8264-8EDCA9EFF1DCQ36834504-4F951D0B-0926-4576-93F7-CF260164ADC1Q36849663-E6E011E9-C51D-4EF7-A16E-728163FF9BFFQ36865033-5DBE6846-AF35-451F-90EF-BB5FBEA8CCD3Q36946809-ECD99127-F8AC-49A1-874E-A6C223D337BCQ38594037-6B844B3B-E791-4482-BEA8-663405D3277FQ38937520-3319A66A-01CB-4B91-A259-BC21F4FA9B40Q41377253-DB37AF76-626E-4C37-9807-62DE82867A49Q49887897-8B7B10E8-DF85-4793-8655-D00558B44A19Q56513677-A3168DE9-D868-495D-A3F2-D82F6C05261AQ57896476-A885FD7C-9DB1-4C56-9727-C22B220AAB24
P2860
The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The dominant role of G12C over ...... in non-small cell lung cancer.
@ast
The dominant role of G12C over ...... in non-small cell lung cancer.
@en
The dominant role of G12C over ...... in non-small cell lung cancer.
@nl
type
label
The dominant role of G12C over ...... in non-small cell lung cancer.
@ast
The dominant role of G12C over ...... in non-small cell lung cancer.
@en
The dominant role of G12C over ...... in non-small cell lung cancer.
@nl
altLabel
The dominant role of G12C over ...... in non-small cell lung cancer
@en
prefLabel
The dominant role of G12C over ...... in non-small cell lung cancer.
@ast
The dominant role of G12C over ...... in non-small cell lung cancer.
@en
The dominant role of G12C over ...... in non-small cell lung cancer.
@nl
P2093
P3181
P1433
P1476
The dominant role of G12C over ...... in non-small cell lung cancer
@en
P2093
Barbora Belsanova
Jindrich Finek
Milos Pesek
Ondrej Fiala
P3181
P356
10.1016/J.CANCERGEN.2012.12.003
P407
P577
2013-01-10T00:00:00Z